Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06176261Phase 2Recruiting

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Role: lead

NCT03417544Phase 2Active Not Recruiting

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Role: lead

NCT00470704Phase 2Completed

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Role: lead

NCT00470847Phase 1Completed

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Role: lead

NCT00496379Phase 2Terminated

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Role: lead

All 5 trials loaded